PoreWise One finding · Human trial · 2012
Study title
Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea
- Kind of evidence
- Human trial 2012 · 42 people · adults with rosacea stage I-II · PMID 22360333
- Measured outcome
- Skin effect
- Year
- 2012
- Who was studied
- 42 adults with rosacea stage I-II
- Sample size
- 42
- Measured outcome
- In a 42-subject randomized, multicenter, double-blind, placebo-controlled pilot trial, a cream containing 5% potassium azeloyl diglycinate and 1% hydroxypropyl chitosan applied twice daily for 28 days reduced facial erythema in rosacea, measured both with a Mexameter and by clinical grading, compared with placebo.
- Certainty
- Low
- Who was measured
- Facial erythema measured by Mexameter and clinical grading over 28 days.
- Study limits
- Pilot sample; rosacea is a disease population.
Where it comes from
- Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea
Published by Journal of Cosmetic Dermatology (Berardesca E, 2012) · Last checked 2026-11-10
Skin concerns studied
Other findings on the same ingredient or concern
- Skin effectA Randomized, Controlled Clinical Trial of a Dermocosmetic Containing Vichy Volcanic Mineralizing Water and Probiotic Fractions in Subjects with Rosacea Associated with Erythema and Sensitive Skin and Wearing Protective Masks
In a randomized split-face controlled trial in people with rosacea-associated erythema and sensitive skin, a dermocosmetic containing mineralizing water, probiotic fractions, hyaluronic acid and niacinamide significantly improved erythema at day 15 (p<0.01) and day 30 (p<0.001), with skin erythema, tightness, dryness, hydration and TEWL improving versus the untreated side (p<=0.05).
Human trial · 2023 · People with rosacea-associated erythema and sensitive skin wearing protective masks · Facial erythema, tightness, dryness, hydration and TEWL over 30 days. · The comparator is usual skin care / an untreated half-face.
- Skin effectTopical nicotinamide for seborrheic dermatitis: an open randomized study
In an open randomized, vehicle-controlled trial of 48 people with mild-to-moderate facial seborrheic dermatitis, 4% nicotinamide cream once daily for 12 weeks reduced the combined erythema/scaling/infiltration score by 75% from baseline versus 35% with the vehicle (p<0.05).
Human trial · 2014 · 48 people · people (36 men, 12 women) aged 20-50 with mild-to-moderate facial seborrheic dermatitis · Combined clinical score of erythema, scaling and infiltration over 12 weeks. · Open-label.
- Skin effectClinical Observation of a Novel Moisturizing Cream for Reducing Neurovascular Hyper-Reactivity in Sensitive Skin
In a 28-day randomized, double-blind split-face trial of 35 people with sensitive skin, a moisturising cream outperformed a control cream in improving pruritus, erythema and transepidermal water loss, while both creams improved sensitive-skin symptoms and signs.
Human trial · 2025 · 35 people · people with sensitive skin · People with sensitive skin applying the creams twice daily for 28 days. · A comparison against another active cream.